{
    "clinical_study": {
        "@rank": "26685", 
        "acronym": "ENCOURAGE", 
        "arm_group": {
            "arm_group_label": "Use of bevacizumab (Avastin \u00ae) - First-line ovarian cancer", 
            "description": "Patient receiving bevacizumab in ovarian cancer first line treatment"
        }, 
        "brief_summary": {
            "textblock": "The French cooperative group GINECO proposes to implement an observational study to describe\n      a real situation, in daily practice tolerance and methods of administration of bevacizumab\n      (Avastin \u00ae)"
        }, 
        "brief_title": "First Line Ovarian Cancer Treatment - Cohort Study", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Epithelial Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Ovarian Neoplasms", 
                "Fallopian Tube Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "detailed_description": {
            "textblock": "Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian\n      tube or primary peritoneal or witch it was decided to initiate a process comprising of\n      Bevacizumab (Avastin \u00ae) in first-line therapy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients aged 18 years and over,\n\n          -  Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will\n             receive bevacizumab (Avastin \u00ae) in first-line therapy\n\n          -  Patients should be informed of the study orally and should not have any objection\n             their data to be processed.\n\n        Exclusion Criteria:\n\n          -  Patient participation in a clinical trial\n\n          -  Patient non-affiliated to a social security scheme."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "\u2022 Patients with epithelial ovarian cancer, fallopian tube or peritoneal with treatment\n        receiving Bevacizumab (Avastin \u00ae) in first-line therapy"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832415", 
            "org_study_id": "ENCOURAGE (GINECO-OV123)"
        }, 
        "intervention": {
            "arm_group_label": "Use of bevacizumab (Avastin \u00ae) - First-line ovarian cancer", 
            "description": "Observation of bevacizumab administration in first line ovarian cancer treatment", 
            "intervention_name": "Bevacizumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "First line treatment", 
            "Ovarian cancer", 
            "Avastin", 
            "fallopian tube or primary peritoneal"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France"
                    }, 
                    "name": "Centre Paul Papin"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France"
                    }, 
                    "name": "Clinique Tivoli"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France"
                    }, 
                    "name": "Institut Bergoni\u00e9"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Clermont Ferrand", 
                        "country": "France"
                    }, 
                    "name": "Centre jean Perrin"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fr\u00e9jus", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier Intercommunal"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France"
                    }, 
                    "name": "institut Paoli Calmette"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nimes", 
                        "country": "France"
                    }, 
                    "name": "Clinique Valdegour"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orl\u00e9ans", 
                        "country": "France"
                    }, 
                    "name": "Centre Hospitalier R\u00e9gional"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dmicheau@arcagy.org", 
                    "last_name": "Douglas MICHEAU-BONNIER", 
                    "phone": "+33 1 42 34 83 23"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Arcagy-Gineco"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gilles Freyer, MD, PhD", 
                    "phone": "+ 33 (0) 478863324"
                }, 
                "facility": {
                    "address": {
                        "city": "Pierre-B\u00e9nite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Centre Hospitalier Lyon-sud"
                }, 
                "investigator": {
                    "last_name": "Gilles Freyer, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France"
                    }, 
                    "name": "Institut Jean Godinot"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Brieuc", 
                        "country": "France"
                    }, 
                    "name": "Clinique Armoricaine de Radiologie"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Herblain", 
                        "country": "France"
                    }, 
                    "name": "ICO Ren\u00e9 Gauducheau"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Civil"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Non Interventional Study Dealing With the Use of Bevacizumab (Avastin\u00ae) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy", 
        "overall_contact": {
            "email": "dmicheau@arcagy.org", 
            "last_name": "Douglas MICHEAU-BONNIER", 
            "phone": "+ 33 1 42 34 83 23"
        }, 
        "overall_official": {
            "affiliation": "ICO de l'Ouest, Site Ren\u00e9 Gauducheau - Saint-Herblain", 
            "last_name": "Dominique BERTON-RIGAUD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: The National Commission for Informatics and Liberties (CNIL in french)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess patient safety and the tolerance of bevacizumab andministered regarding the daily practice of the oncologist.", 
            "measure": "Safety according to CTCAE v4.0 criteria", 
            "safety_issue": "Yes", 
            "time_frame": "Patient will be followed dureing 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832415"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022 Evaluate the efficacy of bevacizumab (Avastin \u00ae) in terms of progression-free survival (PFS) .", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Patient will be followed during 36 months"
            }, 
            {
                "description": "Evaluate the efficacy of the treatment that will be administered at the disease relapse.", 
                "measure": "Efficacy of treatment at relapse", 
                "safety_issue": "No", 
                "time_frame": "Patient will be followed during 36 months"
            }, 
            {
                "description": "Discribe the population that will be registered to make correlation with the safety and efficacy measure", 
                "measure": "Characteristics of the population registered", 
                "safety_issue": "No", 
                "time_frame": "At registration"
            }, 
            {
                "description": "Discribe the reason why patient receive or not bevacizumab in  first line of ovarian cancer treatment", 
                "measure": "Indication and cons indication of bevacizumab in clinical practice", 
                "safety_issue": "No", 
                "time_frame": "At registration"
            }, 
            {
                "description": "Discribe the method that are used during a treatment by bevacizumab in the daily practice", 
                "measure": "Evaluation of monitoring practices of bevacizumab", 
                "safety_issue": "Yes", 
                "time_frame": "The patients will be followed during 36 months"
            }, 
            {
                "description": "Discribe how bevacizumab is administered in the daily practice", 
                "measure": "Evaluation of the modality of use of bevacizumab", 
                "safety_issue": "No", 
                "time_frame": "The patients will be followed during 36 months"
            }
        ], 
        "source": "ARCAGY/ GINECO GROUP", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "ARCAGY/ GINECO GROUP", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "36 Months", 
        "verification_date": "January 2014"
    }
}